For Pain or Not for Pain: Methadone Madness

Slides:



Advertisements
Similar presentations
Common/shared responsibilities between jobs.
Advertisements

Implementing NICE guidance
Medication Management
National Adult Clozapine Titration Chart
Effective Risk Management Strategies in Outpatient Methadone Treatment: Clinical Guidelines and Liability Prevention Curriculum Module 9 Special Populations.
Stimulant Prescribing Training Guide Completion of a ‘Notification of Treatment using Stimulant Medication’ form.
Effective Risk Management Strategies in Outpatient Methadone Treatment: Clinical Guidelines and Liability Prevention Curriculum MODULE 5 Take-Home Medication.
Chronic Pain Management Elaine Wendt, MD. Pain is now “Fifth Vital Sign”
Controlled Substances in the Institutional Setting NYS Council of Health-system Pharmacists May 3, 2009 Victoria A. Hanson, R.Ph., B.S. Pharmacy Consultant.
Sublingual Buprenorphine and Pain
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
.  Introduction to Methadone Maintenance Therapy (MMT)  Introduction to Harm Reduction  Benefits of MMT  One Patient’s Perspective  Misconceptions.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Maryland Cancer Plan Pain Management Committee Suzanne A Nesbit, PharmD, BCPS Clinical Coordinator, Cancer Pain Service Sidney Kimmel Comprehensive Cancer.
DIVISION OF LICENSING & CERTIFICATION, BUREAU OF HEALTH SYSTEMS (BHS) - MDCH (517) Fax (517)
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
American Association for the Treatment of Opioid Dependence, Inc National Conference, Atlanta April 25, 2006 Evaluation of the Impact of Opioid Treatment.
HEALTH CARE SYSTEMS. Health care systems include many agencies, facilities, and people involved in the delivery of health care. Private facilities: Require.
OPIOID SUBSTITUTION THERAPY
PSYCHOTROPIC / PSYCHOACTIVE DRUGS Presented by: Jun Hernandez, R.N. Prepared by: Rhonda Anderson, RHIA.
Respect and Advocacy Sabato A. Stile M.D.. Worldwide, Complex, Public Health Problem affects people from all demographic and social groups and economic.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
PSYCHOTROPIC / PSYCHOACTIVE DRUGS ARE IN THE HEADLINES PRESENTED BY: LIZETH FLORES, RHIT, RAC-CT ANDERSON HEALTH INFORMATION SYSTEMS, INC. APRIL 16 TH,
Pharmacy 483: Steve Riddle, BS Pharm, BCPS QI and Medication Utilization Lead HMC Pharmacy February 22, 2005 Quality Improvement in Pharmacy.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
San Francisco County OBOT Pilot: Pharmacy Aspects Sharon Kotabe, PharmD Associate Administrator for Pharmaceutical Services Associate Clinical Professor.
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Focus Area 17: Medical Product Safety Progress Review November 5, 2003.
State-level Influences on Buprenorphine Utilization: Variations in Opioid Addiction Treatment Lisa M. Lines, MPH and Robin E. Clark, PhD University of.
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
The Heroin Epidemic in rural Maryland Rural Health Learning Collaboration Sept. 28, 2015 James A. Cockey, MD, FACP Deputy Health Officer.
MEDICATION MANAGEMENT P&T COMMITTEE AND FORMULARY MANAGEMENT EMTENAN ALHARBI, Msc CLINICAL PHARMACIST.
Who are Health-System Pharmacists? Pharmacists are healthcare professionals with extensive education and training in the pharmaceutical sciences. Education.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Introduction to Careers in Acute and Ambulatory Settings.
Abuse-Deterrent Opioids: FDA’s Role and Emerging Challenges Jeanne Ireland Principal, Ireland Strategies, LLC 2015 CWAG Annual Meeting.
Medicated Assisted Treatment (MAT) Terry R. Jones Director of Behavioral Health.
Eastern States Residency Conference Dosing of Methadone in the Palliative Care Setting Samantha Bryant, Pharm.D., BCPS PGY2 Drug Information Resident Robert.
미국의 마약류 관리제도 - FDA 와 NIDA 의 조직 및 업무 현황 의약품평가부 이선희.
Benjamin J. Pariser, DO RASE Physician.  This presentation will review the option of Medication Assisted Treatment as part of a comprehensive recovery.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Primary Care Models for Chronic Pain Treatment Melissa Weimer, DO, MCR.
Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.
DEBBIE DONELSON, MD Opioid use for nonmalignant pain management.
Prepared by Dr. Ramin Safakish, MD, FRCPC – March 2016.
Career Opportunities in Health Care Department of Human Resources (HR) at Stronger Memorial Hospital.
CDC Guideline for Prescribing Opioids for Chronic Pain- United States-2016 Gisele J. Girault, M.D. First Choice Healthcare Columbia, SC.
Incidental Medical Services (IMS) Department of
Medication Assisted Treatment
Current Concepts in Pain Management
Examining Potential Misuse of Gabapentin Among Patients Admitted to an Inpatient Behavioral Health Unit Samuel Kubas a, Pharm.D. Candidate 2018; Lucas.
Medication-Assisted Therapy at Coleman Profession Services
San Francisco County OBOT Pilot: Pharmacy Aspects
Opioids – A Pharmaceutical Perspective on Prescription Drugs
A Recommendation from Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from ACOP and APS By Rhys Dela Cruz, Angela Hickey,
OPIOID SAFETY. Indiana Statistics In Summary… About 100 Hoosiers die from drug overdoses every month, many from opioids such as heroin and prescription.
Opioid Prescribing & Monitoring
Pain Management: Patients Maintained on Buprenorphine
Opioids in Butte County
Prescription Drug Monitoring Program
Components of Health Care
Prescription Drug Monitoring Program
National Credentialing Forum 2019 San Diego, CA February
Essentials of Good Pain Care: A Team-Based Approach
Case 1 – 17 yo white female 2 year history of using opioids – prescription post minor surgery, continued use post prescription (non-medical sources) –
Transforming the Delivery of Substance Use Disorder Treatment in States Update August 2019.
Presentation transcript:

For Pain or Not for Pain: Methadone Madness Maria Foy, PharmD, BCPS, CPE Clinical Specialist Palliative Care Abington Memorial Hospital mfoy@amh.org

Objectives Differentiate the use of methadone for pain vs. addiction management Explain information needed to verify a methadone dose for addiction management

Methadone History 1939: developed in Germany to be used as an analgesic in WWII 1949: US obtained methadone from the manufacturing company following the war Early 1960’s: heroin epidemic following WWII 1964: research project was conducted studying methadone for addiction treatment to try to combat the increase abuse of heroin

Patient Case: LO is a 27 year old female who enters the emergency department. She is currently addicted to heroin and recently found out she was pregnant. Currently, patients cannot be admitted to an inpatient facility for heroin detoxification without a special license. Would you allow this patient to be admitted for detoxification in your institution?

Key Policy Elements Define ordering and dispensing processes based on indication of use Analgesia Maintenance therapy for patients enrolled in an Outpatient Treatment Program (OTP) Short term treatment of acute withdrawal in a current opioid abuser if admitted for an alternate medical diagnosis

Key Policy Elements Restrict pain indication use to experts trained and experienced with analgesic use Exception: Unrestricted ordering allowed for patients receiving methadone prior to admission

Key Policy Elements Assure compliance to regulatory agency standards Drug Enforcement Agency (DEA) Substance Abuse and Mental Health Services Administration (SAMSHA) Commonwealth of Pennsylvania

Monitoring Data Time frame: 6 months Total orders reviewed: 105 Clarifications: 11

Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society Published, April 2014: Key Recommendations Patient Assessment: Patient selection should be based on a thorough history, review of medical records and physical examination. Use assessment results to stratify patients based on their risk for substance abuse, co-morbidities, and drug interactions. Education and Counseling: Counsel patients about potential risks and benefits prior to beginning therapy. Advise patients to take methadone as prescribed and comply with follow up monitoring. Notify caregivers about risks for respiratory depression. Baseline Electrocardiograms: Perform ECG exams prior to initiating methadone therapy due risk for QTc interval prolongation.

Guidelines, cont. Alternative Medications: Consider buprenorphine as an option for patients being treated for opioid addiction with risk factors for prolonged QTc intervals. Low Beginning Dose: Methadone treatment should be started at low doses (no more than 30-40 mg daily) and titrated slowly. Urine Drug Testing: Urine drug testing should be performed before initiating therapy and at regular intervals for patients treated for opioid addiction.

Conclusions Development of an institutional methadone policy and order set with decision support has promoted safe and effective use of methadone at our institution Daily review of methadone orders by a pain specialist led to early identification of potential errors

References Pasero C, McCaffrey M. Pain Assessment and Pharmacologic Management. St. Louis, Missouri. Elsevier. 2011. 339-349 McPherson M. Demystifiying Opioid Conversion Calculations. Bethesda, MD. American Society of Health Systems Pharmacists. 2010. 137-143 Federal Narcotic Addict Treatment Act of 1974 (P.L. 93-281) Title 21, Code of Federal Regulations, Section 1306 [39 FR 37986, October 25, 1974). Chou R, Cruciani R, Fiellin D, et.al. Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society. The Journal Of Pain. 2014. 15(4): 321-337 Boutwell A, Rich J. Inpatient Management of the Active Heroin User. Resident and Staff Physician. 2007. 53(3) 1-5